Verrica Pharmaceuticals Q2 Earnings Call Highlights Growth, Strategic Partnerships, and Improved Financial Performance, with Record YCANTH Sales and Strategic Partnership Milestone

Verrica Pharmaceuticals reported a 32.8% sequential quarterly growth in YCANTH dispensed units, reaching a record 13,434 units. The company secured an $8 million payment from Torii Pharmaceutical, strengthening its strategic partnership and achieving a GAAP net income of $0.2 million. Verrica successfully managed operational costs and decreased R&D expenses, but acknowledged potential cash flow concerns. Despite this, the company expressed confidence in sustained growth and anticipated continued success in YCANTH sales and strategic partnerships.